TouchRESPIRATORY got the opportunity to catch up with Alyn Morice (University of Hull, Castle Hill Hospital, Yorkshire, UK) around the unmet needs and treatment of patients with chronic cough (Clinical Trial Identifier: NCT03449134 & NCT03449147).
The abstract ‘Cough Triggers and Symptoms Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Trials of the P2X3 Receptor Antagonist Gefapixant (COUGH-1 and COUGH-2).’ (ABSTRACT NUMBER: 188) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
- What are the unmet needs in the treatment of people with refractory or unexplained chronic cough (RCC/UCC)? (0:20)
- How did you assess cough triggers and symptoms among patients with RCC and UCC? (1:35)
- What were the aims and design of the COUGH-1 and COUGH-2 studies, and what were the findings? (2:34)
- What is the mechanism of action of Gefapixant? (3:57)
- How can we use these findings to address the unmet needs of people with chronic cough? (4:55)
Disclosures: Alyn Morice has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
Share this Video
Related Videos In Chronic Cough
Peter Dicpinigaitis, ERS 2021: Unmet Needs and Advances in Chronic Cough
TouchRESPIRATORY got the opportunity to catch up with Professor Peter Dicpinigaitis (Albert Einstein College of Medicine and Montefiore Cough Center, NY, USA) to learn more about the unmet needs in chronic cough and recent clinical advances. Questions What are the unmet needs in the treatment of patients with refractory or unexplained chronic cough (RCC or […]
Peter Dicpinigaitis, ERS 2021: Gefapixant for Chronic Cough
It was a pleasure to meet with Professor Peter Dicpinigaitis (Albert Einstein College of Medicine and Montefiore Cough Center, NY, USA) to discuss the findings from the COUGH-1 and COUGH-2 studies, investigating gefapixant for the treatment of patients with chronic cough. The abstract ‘Patient-reported chronic cough severity over 52 weeks in two phase 3 trials […]
Jacky Smith, ATS 2021: Findings from the COUGH-1 and COUGH-2 Study Data
We were delighted to talk with Professor Jacky Smith (School of Biological Sciences, The University of Manchester, Manchester, UK) around cough frequency with gefapixant in patients with chronic cough. The abstract ‘Objective Cough Frequency with Gefapixant in Chronic Cough: A Pooled Analysis of Two Phase 3 Randomized, Controlled Clinical Trials (COUGH-1 and COUGH-2).’ was presented […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!